Biosimilar switching: is there a nocebo effect that contributes to treatment failure?

More research is required to explore whether the nocebo effect on biosimilar switching may contribute to biologic treatment failure, clinicians say. In a review article of non-medical biosimilar switching the nocebo effect was defined as disease worsening or occurrence of a new or worsening adverse event resulting from a patient’s negative expectations toward a new ...

Already a member?

Login to keep reading.

© 2022 the limbic